I54 Stock Overview
A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.68 |
| 52 Week High | HK$1.79 |
| 52 Week Low | HK$0.58 |
| Beta | 0.73 |
| 11 Month Change | 7.09% |
| 3 Month Change | -13.92% |
| 1 Year Change | -61.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| I54 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.1% | 2.6% | 4.5% |
| 1Y | -61.4% | -16.4% | 13.4% |
Return vs Industry: I54 underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: I54 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| I54 volatility | |
|---|---|
| I54 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I54 has not had significant price volatility in the past 3 months.
Volatility Over Time: I54's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,040 | Yuelei Shen | biocytogen.com.cn |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
| I54 fundamental statistics | |
|---|---|
| Market cap | €321.74m |
| Earnings (TTM) | -€31.15m |
| Revenue (TTM) | €102.27m |
3.1x
P/S Ratio-10.3x
P/E RatioIs I54 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I54 income statement (TTM) | |
|---|---|
| Revenue | CN¥800.58m |
| Cost of Revenue | CN¥213.99m |
| Gross Profit | CN¥586.58m |
| Other Expenses | CN¥830.40m |
| Earnings | -CN¥243.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 73.27% |
| Net Profit Margin | -30.46% |
| Debt/Equity Ratio | 53.1% |
How did I54 perform over the long term?
See historical performance and comparison